ISRCTN93360820
Completed
Not Applicable
Enhancing cognition in bipolar disorder
Suffolk Mental Health Partnership NHS Trust (UK)0 sites20 target enrollmentJuly 16, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bipolar disorder
- Sponsor
- Suffolk Mental Health Partnership NHS Trust (UK)
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. All patients must be able to give informed written consent to participate in the study
- •2\. Aged 18 to 65
- •3\. English should be spoken fluently
- •4\. Participants should be literate and have normal or corrected to normal eyesight
- •5\. All patients must have met Diagnostic and Statistical Manual of Mental Disorders \- Fourth Edition (DSM IV) criteria for Bipolar I disorder in the past i.e. they must have had an episode of mania or a mixed affective state
- •6\. The Hamilton Depression Rating Scale and Young Mania Scale scores must both be less than eight
Exclusion Criteria
- •1\. Patients who currently fulfill criteria for mania, a mixed affective state, hypomania or major depression
- •2\. Patients who score less than or equal to 24 on the Mini\-Mental State Examination (MMSE). All patients with a diagnosis of dementia will be excluded after review of case\-records and/or discussion with their clinician
- •3\. Current diagnosis of alcohol or drug dependence based on DSM IV criteria
- •4\. History of learning disability (or Wechsler test of Adult Reading score \<90\) or dyslexia
- •5\. Any known neurological illness (including narcolepsy)
- •6\. Unstable medical illness that may affect cognition (untreated thyroid disease, type I diabetes mellitus or current treatment with steroids)
- •7\. Have received electroconvulsive therapy in the past three months
- •8\. Patients taking herbal remedies such as St John?s Wort or Gingko Biloba
- •9\. Moderate or severe hypertension. All patients should have blood pressure measurements within normal limits (i.e. systolic blood pressure less than or equal to 160 and diastolic blood pressure less than or equal to 90\) prior to drug administration
- •10\. Known history of angina or cardiac arrhythmias
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Enhancing cognition in bipolar disorder - Enhancing cognition in bipolar disorderEUCTR2004-005010-37-GBSuffolk Mental Health Partnerships Trust20
Recruiting
Phase 2
Improvement of cognitive function in bipolar disorder by aripiprazole adjunct treatmentF31.7Bipolar affective disorder, currently in remissionDRKS00004316Bristol-Myers Squibb GmbH & Co. KGaA 52
Completed
Phase 3
A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar DisorderBipolar DisorderNCT01934972University of Arizona30
Active, not recruiting
Not Applicable
Cognitive impairment in bipolar disorder treated with aripiprazole (memory, alertness, etc.)Bipolar disorder is among the most severely debilitating diseases. Patients with bipolar disorder generally experience high rates of relapse, a chronic recurrent course, lingering residual symptoms, functional impairment, psychosocial disability and diminished well-being. More recent data have underlined the importance of neurocognitive impairments in the euthymic state including impairments in attention, memory and executive function.EUCTR2009-017581-22-DEDepartment of Psychiatry and Psychotherapy, Charity University Medicine
Unknown
Not Applicable
Assessment of Cognitive Functions in Bipolar PatientsBipolar DisorderNCT04091828Assiut University72